An Open-Label, Single-Dose, Phase 1 Study to Evaluate the Pharmacokinetics and Safety of BMS-986278 in Participants With Normal Renal Function, Participants With Severe Renal Impairment, and Participants With End-Stage Renal Disease on Intermittent Hemodialysis
Latest Information Update: 15 Mar 2025
At a glance
- Drugs Admilparant (Primary)
- Indications Idiopathic pulmonary fibrosis; Liver disorders; Pulmonary fibrosis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 08 Jan 2025 Status changed from not yet recruiting to recruiting.
- 16 Dec 2024 New trial record